Alphabet's GV Leads Funding in Gene Editing Company Verve Therapeutics

GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.

Comments

Popular posts from this blog

Oppo K11 5G With Snapdragon 782G SoC, 100W Fast Charging Launched: Price, Specifications